Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Morgan Stanley Downgrades Bristol-Myers Squibb Co. (BMY) to Equalweight
August 5, 2016 1:24 PM EDTMorgan Stanley downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Overweight to Equalweight.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $75.32 yesterday.
... MoreDeutsche Bank Comments on Bristol-Myers Squibb (BMY) Opdivo News; Analyst Says Merck (MRK) Not Guaranteed to be Alone in Front-Line Setting
August 5, 2016 11:25 AM EDTDeutsche Bank analyst Gregg Gilbert commented on Bristol-Myers Squibb (NYSE: BMY) and Merck (NYSE: MRK) following news BMY's Opdivo failed to meet the primary endpoint for CHECKMATE-026. In his view, the news is clearly positive for Merck and negative for Bristol-Myers, but he said Merck is not guaranteed to be alone in the front-line setting.
"We need more time to fully assess the implications of this move and thus are not changing our ratings or estimates here (both rated Hold), but... More
Bristol-Myers (BMY) Opdivo Trial Miss a 'Seismic Event', BMO Capital Says (MRK)
August 5, 2016 10:00 AM EDTBMO Capital analyst Alex Arfaei weighed in on Bristol-Myers Squibb Co. (NYSE: BMY) after the company announced that announced that in CheckMate-026 (CM-026), a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Opdivo did not meet the trial's primary endpoint of progression-free survival (PFS) in patients expressing PD-L1 >= 5%. Arfaei calls this a significantly negative for BMY and positive for Merck (NYSE:... More
SunTrust Robinson Humphrey Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral
August 5, 2016 9:30 AM EDTSunTrust Robinson Humphrey downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Buy to Neutral with a price target of $68.00 (from $86.00).
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click... More
Bristol-Myers Squibb (BMY) Falls 22% After Shares Resume Trading
August 5, 2016 8:32 AM EDTBristol-Myers Squibb (NYSE: BMY) Falls 22% After Shares Resume Trading
... MoreMerck (MRK) Surges After Bristol-Myers Squibb's (BMY) CheckMate -026 Trial Fails
August 5, 2016 8:24 AM EDT(Updated)
Shares of Merck (NYSE: MRK) surged pre-market Friday after Bristol-Myers Squibb (NYSE: BMY) released disappointing results from CheckMate -026, phase 3 study of Opdivo for treatment of patients with NSCLC.
The study showed Opdivo did not meet trial... More
